Hematologic malignancies (blood cancers), which impact the normal production and function of blood cells, often begin in bone marrow where stem cells develop into white blood cells, red blood cells, or platelets. These types of cancers occur when an uncontrolled growth of abnormal cells overtakes the development of normal blood cells, interfering with the regular functions of those cells. Hematologic cancers can be classified into three categories: leukemia, lymphoma, and multiple myeloma.
Developing quality improvement programs aimed at reducing health care disparities and improving the standard of care received by patients with hematologic cancers are key priorities in ACCC's educational programming. Leverage our recent research and explore practical, actionable resources that you can implement in your cancer program today.
Managing chronic lymphocytic leukemia (CLL) after double exposure to Bruton’s tyrosine kinase (BTK) and B-cell leukemia/lymphoma 2 (BCL2) inhibitors requires a tailored approach. This guide provides considerations and strategies to optimize outcomes for these patients.
